RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and GLP-1 hormones ... The increase during the quarter was primarily due to the progress made in our REMAIN-1 and ...
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial ... and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer ...
Advanced BioScience Laboratories (ABL), a biotherapy, oncolytic and viral vector contract development ... "We have known Ascend and followed its progress in creating effective and high-quality gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback